Imaging Kv1.3 Expressing Memory T Cells as a Marker of Immunotherapy Response.

ABSTRACT: Immune checkpoint inhibitors have shown great promise, emerging as a new pillar of treatment for cancer; however, only a relatively small proportion of recipients show a durable response to treatment. Strategies that reliably differentiate durably-responding tumours from non-responsive tumours are a critical unmet need. Persistent and durable immunological responses are associated with the generation of memory T cells. Effector memory T cells associated with tumour response to immune therapies are characterized by substantial upregulation of the potassium channel Kv1.3 after repeated antigen stimulation. We have developed a new Kv1.3 targeting radiopharmaceutical, [18F]AlF-NOTA-KCNA3P, and evaluated whether it can reliably differentiate tumours successfully responding to immune checkpoint

SUBMITTER: Goggi JL 

PROVIDER: S-EPMC8909107 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature